73264319
:
Viking Therapeutics stock fell after Novo Nordisk reported positive phase 1 results for experimental obesity drug amycretin. Amycretin achieved similar weight loss as Viking's VK2735 did in a phase 2 study. However, Viking could still have a big opportunity with VK2735 and its promising experimental NASH drug.
73264319 : Viking Therapeutics stock fell after Novo Nordisk reported positive phase 1 results for experimental obesity drug amycretin. Amycretin achieved similar weight loss as Viking's VK2735 did in a phase 2 study. However, Viking could still have a big opportunity with VK2735 and its promising experimental NASH drug.
Super Dave 73264319 : which makes no sense since, why their weightloss drug woukd fall out of favor. norvo will never be able to keep up with demand.